Type of Presentation

Oral Presentation

Location

SHAN 3461

Start Date

9-11-2024 4:15 PM

End Date

9-11-2024 4:45 PM

Comments

Plaintext of abstract if preferred:

Early assessment of therapeutic efficacy is a critical need in cancer treatment. It can take months or even years to rule out ineffective treatments through imaging. Next-gen sequencing (NGS) has made it possible to collect and sequence circulating tumor DNA (ctDNA) from longitudinal blood samples, potentially providing rapid evaluation of treatment efficacy. While ctDNA data continues to be collected on a wide variety of cancers and treatment types, it is still unclear which ctDNA biomarkers are most indicative of treatment success or failure. We present mechanistic models for ctDNA shedding that are capable of capturing the diverse kinetics of ctDNA under targeted therapy, chemotherapy, surgery, and radiotherapy. We use ctDNA metrics to define dynamic biomarkers of treatment efficacy and show that they outperform existing ctDNA biomarkers. Our work demonstrates ways in which early ctDNA can be used to quickly and reliaby predict treatment response or lack thereof.

Share

COinS
 
Nov 9th, 4:15 PM Nov 9th, 4:45 PM

Early ctDNA kinetics as a dynamic biomarker of cancer treatment response

SHAN 3461